NTx Appoints Steven Evans as Chief Scientific Officer
Nature's Toolbox (NTx) a life sciences company building next generation platforms to manufacture RNA and protein, today announced the appointment of Steven Evans, Ph.D. as Chief Scientific Officer and Senior Vice President of R&D.
With a distinguished career at global pharmaceutical leaders like Pfizer and GSK, Steve brings a wealth of drug development strategy and knowledge, as well as scientific leadership spanning multiple disease areas. His expertise in translational pharmacology and immunology has been pivotal in the development of different drug modalities from discovery through clinical phases as well as driving organizational investment into novel drug development platforms and first-in-class assets. At NTx, Steven will leverage his extensive skills in executive leadership, strategic planning, and cross-collaboration to drive the company's R&D initiatives to new heights.
Following the recent $47.5M Series B financing raise and a more than an eight-year sprint inventing and advancing NTx technologies, the founder and former CSO of NTx, Alex Koglin, has decided to take time to recharge and refresh.
"NTx is founded on Alex's brilliant insights. He has built an outstanding team of scientists and positioned the company for accelerated growth," said Jamie Coffin, CEO of NTx. "We are grateful for his leadership and his significant contributions to the company's success. As we take our company to the next level, we are excited to welcome Steve to the leadership team."
"NTx has pioneered a platform that stands to revolutionize the field of drug discovery and development, dramatically cutting down both the cost and time required to deliver vital medications to the market," said Steve Evans. "Joining the team at this pivotal moment for the company is truly exciting. I look forward to further advancing our technology."
For more information about NTx, please visit: https://www.ntxbio.com.
About NTx
Nature's Toolbox, Inc. (NTx) is advancing the healthcare industry with their next generation biomanufacturing solutions. NTx, based in Rio Rancho, New Mexico, is developing innovative systems like NTxpress® and NTxscribe® to enable manufacturing of mRNA vaccines and protein therapeutics in an eco-friendly and sustainable way. These easily scalable processes enable NTx's platform to scale from personalized medicine dosage to pandemic volume. To learn more about their game-changing approach, visit their website at https://www.ntxbio.com.
News published on and distributed by:
